BIOMAT Database Logo BIOMAT Database Logo

Effect of ipratropium bromide (atrovent) inhalation in chronic bronchitis. 1985

S Kashyap, and S K Jindal, and S K Malik

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009241 Ipratropium A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. N-Isopropylatropine,(endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane,Atrovent,Ipratropium Bromide,Ipratropium Bromide Anhydrous,Ipratropium Bromide Monohydrate,Ipratropium Bromide, (endo,anti)-Isomer,Ipratropium Bromide, (exo,syn)-Isomer,Ipratropium Bromide, endo-Isomer,Itrop,Sch-1000,Sch-1178,N Isopropylatropine,Sch 1000,Sch 1178,Sch1000,Sch1178
D010366 Peak Expiratory Flow Rate Measurement of the maximum rate of airflow attained during a FORCED VITAL CAPACITY determination. Common abbreviations are PEFR and PFR. Expiratory Peak Flow Rate,Flow Rate, Peak Expiratory,PEFR
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory

Related Publications

S Kashyap, and S K Jindal, and S K Malik
Ipratropium bromide aerosol in chronic bronchitis.
October 1977, Irish medical journal,
S Kashyap, and S K Jindal, and S K Malik
Nebulised ipratropium bromide and salbutamol in chronic bronchitis.
January 1980, The British journal of clinical practice,
S Kashyap, and S K Jindal, and S K Malik
Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution.
May 1987, British medical journal (Clinical research ed.),
S Kashyap, and S K Jindal, and S K Malik
[Effect of Atrovent (ipratropium bromide) on the mechanics of respiration in patients with chronic obstructive pulmonary disease].
March 1986, Pneumonologia polska,
S Kashyap, and S K Jindal, and S K Malik
[Inhalation of high-doses of ipratropium bromide (Atrovent) does not cause any changes in systemic or pulmonary hemodynamics].
February 2000, Casopis lekaru ceskych,
S Kashyap, and S K Jindal, and S K Malik
Nebulized ipratropium bromide in ventilator-assisted patients with chronic bronchitis.
May 1994, Chest,
S Kashyap, and S K Jindal, and S K Malik
Ipratropium bromide (Atrovent) nasal spray. A new treatment for rhinorrhea.
July 1996, The Nurse practitioner,
S Kashyap, and S K Jindal, and S K Malik
The effect of ipratropium bromide (Atrovent) on the air conditioning capacity of the nose.
June 1985, Clinical otolaryngology and allied sciences,
S Kashyap, and S K Jindal, and S K Malik
Ipratropium bromide inhalation for allergic rhinitis and chronic cough.
February 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S Kashyap, and S K Jindal, and S K Malik
Ipratropium bromide (Atrovent) in childhood asthma: a cumulative dose-response study.
February 1989, Annals of allergy,
Copied contents to your clipboard!